Posted on

Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness

Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness

The largest and most important Psychedelic Medicine Conference in the Southern Hemisphere

Vancouver, British Columbia–(Newsfile Corp. – November 16, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that it is a Major Supporter of the upcoming International Summit on Psychedelic Therapies for Mental Illness taking place November 17-20, 2021.

Mind Medicine Australia (“MMA”) will hold a two-day online International Summit on Psychedelic Therapies for Mental Illness in November 2021 (the “Summit”), bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, investors, Government, law and policy leaders, business, industry, insurers, consumers, and other interested stakeholders. The Summit will provide the opportunity to learn from the global leaders in the psychedelic renaissance including Dr. Rick Doblin (USA), Professor Roland Griffiths (USA), Professor David Nutt (UK), Dr. Gabor Mate (Canada), Professor Robin Carhart-Harris (UK), Dr Alberto Villoldo (USA) and other thought leaders like Johann Hari.

The event will also feature a two-day pre-Summit Introductory Workshop Program (November 17-18) led by Nigel Denning, Dr. Tra-ill Dowie with world-leading therapist trainer Dr. Bill Richards (USA) from Johns Hopkins University. It is for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the treatment of mental illness.

Philip Young CEO & Director of Lobe Sciences stated, “We are very happy to partner with Mind Medicine Australia by sponsoring this conference and exploring further collaborations as they seek to bring the reality of psychedelic medicine to medical practitioners and their patients in Australia.”

Executive Director of MMA Tania de Jong AM says, “There is a massive renaissance of interest in these medicines, especially now. When we started MMA there was just one commercial start-up globally; now there are new companies launching weekly. With accelerating mental illness across the community due to the Covid-19 crisis we simply do not have the tools to heal the millions who are suffering. These medicines provide potential for healing for those who have tried multiple different treatments, often over decades, without success. We are very excited to hear from the world class leaders at our Global Summit. They will share valuable insights, data and science, and educate practitioners, consumers, insurers, investors, business, industry, government, academics and the broader community about this rapidly emerging field.”

Ilan Hayman, Operations Manager of Mind Medicine Australia and Advisory Board Member of Lobe Sciences said, “Our program features a world class line-up of talks, workshops, hot spots, panel conversations and creative moments. The International Summit on Psychedelic Therapies for Mental Illness is an excellent educational opportunity to gain an in-depth understanding of this long-overdue innovation in mental healthcare. Both MDMA and psilocybin assisted therapies have been shown to be successful in treating depression, social anxiety in autistic adults, post-traumatic stress disorder (PTSD), end-of-life stress and anxiety and addiction. They are now being trialed for anorexia, obsessive-compulsive disorder (OCD), and dementia, among many other conditions. I am very happy that Lobe has partnered with Mind Medicine Australia as we seek to expand the treatment options available to medical practitioners and their patients to treat a range of chronic mental health conditions.”

For information and to register for the International Summit on Psychedelic Therapies for Mental Illness and the Psychedelic Therapist Introductory Workshop, please visit: https://summit.mindmedicineaustralia.org/.

About Mind Medicine Australia

Mind Medicine Australia was founded by social entrepreneurs Peter Hunt AM and Tania de Jong AM following their successful experience setting up other charities and working with people diagnosed with a mental illness. It is an Australian registered charity (with DGR 1 status) seeking to broaden the treatment paradigm available to medical practitioners and their patients and improve treatment effectiveness by establishing, safe, accessible and effective Psychedelic-Assisted Psychotherapy in Australia to help prevent further suffering and suicides caused by mental illness. MMA’s focus in wholly clinical.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.

Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103631

Posted on

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory

  • Red Light Holland is continuing its groundbreaking working synergies with Shaman Pharma Corp. and their cGMP laboratory partner, CCrest Laboratories Inc. who holds a Controlled Drugs and Substances License issued by Health Canada

  • Red Light Holland previously completed two exports, under Health Canada psilocybin import permits, for commercial sale of psilocybe truffles grown in the Company’s farm in Horst, Netherlands to CCrest Laboratories’ cGMP pharmaceutical laboratory in Montreal, Canada

  • Red Light Holland’s psilocybe truffles are being evaluated and tested by CCrest Laboratories for:
    • The suitability of Red Light Holland’s naturally occuring psilocybin as a source of active pharmaceutical ingredients (“API”) for scientific and potentially medical and therapeutic purposes
    • Providing Red Light Holland customers with scientific information regarding relative strength of different truffles strain sold
    • Moving towards dose standardization in anticipation of Oregon measure 109 and potentially other world wide locations.

  • Red Light Holland and CCrest Laboratories continue to demonstrate their strong commitment to the highest regulatory compliance standards

Toronto, Ontario–(Newsfile Corp. – November 15, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles, is pleased to announce that it has received the first reports, produced by Shaman Pharma Corp. and CCrest Laboratories Inc. under Health Canada approval, evaluating the suitability of Red Light Holland’s natural psilocybin as a source of active pharmaceutical ingredients (“API”) for scientific and potentially medical and therapeutic purposes.

“This report is a step forward both for the recreational market, as well as the pharmaceutical market interested in naturally occurring psilocybin. We’re excited to share some of the scientific findings from the report on the three different truffles strains that we grow in The Netherlands, for our newly launched variety of products such as the iMicrodose Triniti pack, featuring all three strains that were tested,” said Todd Shapiro, CEO and Director of Red Light Holland. “Red Light Holland and Shaman Pharma are once again pushing the limits, having a true ally and partner with cutting-edge scientific expertise to evaluate our truffles. This is certainly a major milestone in Red Light Holland’s mandate of pursuing research and development, product advancements, technology and applied science which bolsters our Scarlette Lillie Science and Innovation division.”

Red Light Holland initially supplied its truffles in March 2021, with a second shipment in August 2021, to CCrest Laboratories, a cGMP pharmaceutical laboratory in Montreal enabled with a Health Canada Controlled Drugs and Substances license, specializing in highly regulated narcotics, including psychedelics. The raw materials proved to be suitable to complete the first phase of the scientific research, which included the development of proprietary analytical methods and protocols, such as assays to determine the presence and concentration of psilocybin and performing extraction to isolate psilocybin, from both fresh and dried sclerotia.

These cGMP compliant scientific methods and protocols of Quality Control, Analysis and Extraction are aimed at developing intellectual property for achieving the industrial-scale commercialization of medical purpose psychedelic substances in this emerging pharmaceutical sector. Exceeding the exacting regulatory requirements opens a new realm of possibilities for disruptive healthcare innovation using natural psychedelic mushroom derivatives.

Given the prohibited status of psilocybin, listed along Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances, science on the subject has remained limited, mostly manifested in the literature and methods produced in academic settings. Some of the known compounds in magic mushrooms – psilocybin, psilocin, norpsilocin, baeocystin, norbaeocystin, and aeruginascin – present similarities in their molecular structure, yet these chemicals can react with significant variation in the laboratory, and their little-known differences in behavior once inside the body could prove complimentary or synergistic, possibly creating a so-called entourage effect.

The report demonstrates that different solvents, such as water and methanol in various ratios, render extraction at different speed and quantity and can transform the compounds in the process. Using the same materials with various process modifications, the individual effect on an organism (e.g., human) could yield a significant difference in cognitive experience. In human metabolism, psilocybin is primarily a pro-drug that is dephosphorylated to active metabolite psilocin. One variation in the extraction method has yielded exclusively psilocin, indicating it could bypass dephosphorylation in the metabolism. These variations can lead to discovering innovative delivery mechanisms, which could provide better control between the onset speed and effective duration.

As one of the involved scientists explains, they have positively answered the hypothesis “what if?…” Red Light’s truffles are a viable source of active compounds, the next objective is using the compounds in the development process of pharma-grade ingredients or creating standardised doses for legal markets. With the first phase considered a success, the companies are wrapping up this work and moving to the next phases.

The scientists are now focusing on optimizing the extraction yield, as well as generating comparative data between the raw material attributes: genetic, size and weight, water content, and so on, as factors that can establish the proportions and total content of the various compounds, in a newly developed proprietary protocol identified as SP1-173-L – Qualitative and Quantitative Determination of Psilocybin & Psilocin truffles and mushrooms by Liquid Chromatography.

The objective of the SP1-173-L protocol is to assess the content of compounds in three species of truffles: Galindoi, Mexicana & Tampanensis, using the Liquid Chromatography method developed at CCrest Laboratories. The study will address the suitability of the analytical procedure, the assay of compounds in the three varieties of truffles and the variability of contents within the species and truffles size. Water content will be determined for all specified and sized samples. The tests will be performed by trained analysts at CCrest Laboratories, ensuring that the facilities and instrumentation are properly calibrated and qualified as needed. The laboratory systems will be in compliance with applicable regulations and in-house general laboratory procedures.

This protocol defines the experimental design and the data to be collected for the comparison of compounds contained in truffles of different size and species. The assay is conducted on three species of truffles, supplied by Red Light Farm. The data evaluation consists of:

  • Evaluation of the suitability of the analytical procedure SP1-173-L (precision and repeatability of injection).
  • The comparison of content of compounds will be obtained from three different samples from each species: small truffles, big truffles and a mix of small and big truffles, for a total of nine samples.
  • Determination of water content in the three different species of fresh truffles: Galindoi, Mexicana and Tampanensis.

In previous assays detailed in the reports, the Mexicana species appeared to be the most potent by a few percentage points, measuring at just under 1mg/gram of combined psilocybin and psilocin. The Tampanensis showed the highest proportion of psilocybin, the psilocin composing less than 10% of the total. The Galindoi, while the least potent overall, demonstrated the most balanced mix, with the psilocin equal to slightly more than 50% of the psilocybin content. While these three species are currently sold legally in the Netherlands, due to regulatory restrictions it has not been possible before now to achieve this level of comparison in a formal cGMP setting.

“We are advancing in uncharted territory where we are discovering a promising horizon, so we are definitely motivated to keep moving forward. This scientific work barely scratches the surface of possibilities, we are excited to increasingly deploy our proven pharma abilities in deepening the qualification of Red Light Holland`s truffles as a source of novel therapeutic ingredients,” commented Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories. “While synthetic psychedelics are dominating the field, it makes sense to look at the original natural source, because something like an entourage effect would not be reproduced by synthesis. Just as much-hyped artificial cannabinoid analogues were not successful in displacing phytocannabinoids (marijuana), we anticipate the development of a tremendous share of demand for natural psychedelic mushroom derivatives, initially to supply research before cascading downstream to larger markets. Our approach, which is scientific, rigorous, and calculated, is also tailored to the real-world movement out there, the active audience for psychedelics, including many scientists, who are demanding natural origins.”

Red Light Holland continues to establish itself as a leader in the recreational sector and push for legal, responsible and safe access to natural psychedelic truffles/mushrooms while Scarlette Lillie Science and Innovation pursues research and development, technology, and applied science.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.

For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

Forward-Looking Statements

About Shaman Pharma Corp.

Shaman Pharma is a federally registered Canadian corporation with the mission to power outstanding psychedelic life science innovation. Accelerating time-to-market through its portfolio of assets, Shaman launches and consolidates revenue-driven pharma-biotech life sciences ventures focused on supplying psychedelic drugs & novel active ingredients.

Forward-Looking Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to: statements with respect to the evaluation and testing of the Company’s naturally occurring psilocybe truffles by CCrest Laboratories for scientific and medical purposes; the potential of the Company’s products being used for scientific and medical purposes; statements with respect to the Company’s expansion into the mental wellness pharmaceutical sector; the future sharing of the test results with the Company’s customers and shareholders; and the Company’s ability to establish itself as the leader in the recreational psychedelics sector.

Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the COVID-19 pandemic impact on the Canadian economy and Red Light Holland’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Red Light Holland’s business; there will be a demand for Red Light Holland’s products in the future; no unanticipated expenses or costs arise; the Company will be able to continue to develop products that are allowed to be imported and sold under Health Canada’s import permit; and the partnership with Shaman Pharma Corp. will help Red Light Holland to achieve its business goals. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to continue as a going concern; the inability of the Company to obtain all necessary governmental and/or other regulatory approvals, licenses, and permits necessary to operate and expand the Company’s facilities; the effect of regulatory and/or political change and its effect on the legislation and regulations surrounding the psychedelics industry; p negative perception of the medical-use and adult-use psilocybin industry; the inability of CCrest to complete the planned testing of the Company’s products; the potential unviability of psilocybin for medical and/or scientific purposes; the inability of the Company to continue its growth; the Company’s limited operating history; reliance on management; the Company’s requirements for additional financing; and competition for mental health and wellness investments.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Posted on

Smoke weed with a veteran on DMT: issue 23

Here’s what’s in store for you in today’s issue:

🍄 How weed influences your trip

🍄 Healing veterans with DMT

🍄 The results from the biggest psilocybin study ever!

🍄 At-home ketamine therapy

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Functional Mushrooms for Health & Nutrition with FreshCap CEO Tony Shields

In the episode of the Daily Mushroom Podcast, we have Tony Shields, CEO of FreshCap. Tony’s knowledge on mushrooms is deep and expansive and stems from a childhood fascination with these magnificent fungi. If you want to learn more about the benefits of functional mushrooms, this podcast is for you.

Therapeutic banner

The results from the world’s biggest psilocybin trial are in!

COMPASS Pathways’ (CMPS) stock dropped nearly 30% after announcing mixed study findings and Q3 financial results on Monday.

The company conducted a trial on 233 patients to determine the best psilocybin dose for treatment-resistant depression (TRD).

All three groups showed improvements the day after receiving the dose. The group with the largest dose had the best results, with 36.7% of patients showing at least a 50% decrease in depression scores and 29.1% in remission at week 3. A quarter of the patients showed sustained improvements until week 12.

Unfortunately, 12 patients experienced serious adverse events such as suicidal ideation or self harm, but these behaviours are common in patients with TRD.

The company is preparing for a larger trial beginning next year.

COMPASS also announced that it lost $15.8 million or $0.38 per share in Q3, an improvement compared to its $1.30 loss per share in Q3 of last year.

Here’s a graph that shows the impact on levels of depression reported by trial patients: 👇🏽

Why ketamine is so effective at preventing suicide

Researchers have known for years that ketamine can reduce depression symptoms and suicidal ideation in as little as 24 hours, but a recent study helps us understand why it’s so beneficial.

The study showed that a single dose of ketamine rapidly improved cognitive function, problem-solving abilities, and distorted thinking in suicidal patients.

“Being able to think more clearly can make someone feel less suicidal,” explains Ravi. N. Shah, MD, one of the researchers.

Ketamine was more effective than Midazolam, a benzodiazepine used as a sedative for surgeries. After the dose, suicidal ideation was diminished for up to 6 weeks.

Treating alcoholism and depression with half the dose

Cybin (CYBN) announced that its psilocybin formulation for depression and alcoholism, CYB003, could be more effective than oral psilocybin.

The company conducted preclinical testing on multiple species of animals. Researchers found that CYB003 has nearly double the brain penetration compared to oral psilocybin, resulting in a 50% reduction in dosage, variability, and onset time.

A smaller dosage has potential to reduce negative side effects such as nausea. The formulation could lead to shorter sessions which would make treatment more affordable!

inspirational banner

Can weed make your trip better?

A bit of weed could make your trip more spiritual and less scary.

A survey of 321 people suggests that using cannabis while on psychedelics increases the odds of mystical experiences, ego deaths, and intense visuals. 

The data also showed that low doses of cannabis reduced the chances of bad trip, whereas high doses increased feelings of fear and insanity.

Healing veterans with DMT

In honour of Veteran’s Day, we’re sharing how a Special Ops veteran cured his chronic pain and PTSD with DMT.

Asher Gibson was diagnosed with PTSD and traumatic brain injury after countless combats across the world. Prescription medications began to dominate his life, so he turned to psychedelic healing.

After smoking DMT, the powerful compound found in ayahuasca, Asher was blasted out of his body and traveled through different dimensions to the beginning of time.

“I remember my whole head being ecstatic and numb, like the most wonderful electrical massage on my brain. The feeling moved down my neck and shoulders and eventually filled my entire body.”

After the trip, Asher’s debilitating neck and shoulder pain was almost non-existent and his mental state subsided to manageable levels. He is no longer dependent on prescription drugs.

“While DMT isn’t the magic button that fixes everything, I believe it’s a powerful guide to help you do the work yourself,” he explains.

To bring this kind of relief to other veterans, consider supporting the Heroic Hearts Project – a non-profit organization that provides ayahuasca retreats for veterans with combat experience or military sexual trauma.

Insurance coverage for ketamine therapy

A major hurdle of making psychedelic therapy accessible to all will be getting the treatment covered by insurance.

That’s why we’re excited to share that Novamind (NM) has secured coverage for ketamine treatments from four major health insurance providers: Blue Cross Blue Shield, the University of Utah, PEHP Health & Benefits and MBA Benefit Administrators!

The company’s Chief Medical Officer says that this a promising signal that insurance providers are interested in more effective mental health treatments as research emerges.

Novamind has also opened a call center dedicated to insurance verification to ensure that patients are approved and reimbursed as quickly as possible.

business banner

Congrats to the top psychedelic companies of 2021!

These leading psychedelic companies were recognized for their accomplishments at Microdose Psychedelic Insights’ Wonderland: Miami – the world’s largest psychedelic business event, ever.

Company of the Year: Cybin Inc. (CYBN)

Psilocybin Company of the Year: MycroDose Therapeutics (private)

Ketamine Company of the Year: Field Trip Health (FTRP)

Ibogaine Company of the Year: MindMed (MNMD)

DMT Company of the Year: Psilera Bioscience (private)

LSD Company of the Year: MindMed (MNMD)

MDMA Company of the Year: MAPS (non-profit)

Platform Company of the Year: MindMed (MNMD)

Drug Development Company of the Year: Awakn Life Sciences (AWKN)

Retreat of the Year: Synthesis

Clinic of the Year: Awakn Life Sciences (AWKN)

B2C Tech Company of the Year: Fireside Project (non-profit)

B2B Tech Company of the Year: MycroDose Therapeutics (private)

Try psychedelic therapy at home in these states

TripSitter Clinic Corp. now offers at-home ketamine therapy in 10 states! 

The company, which is part of Origin Therapeutics’ portfolio, expanded its services to eight new states: Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia, in addition to California and Illinois.

Patients can receive a prescription for oral ketamine after a virtual consultation with a physician. They then take the medication at home with virtual guidance, followed by therapy sessions.

This is a promising step toward greater ketamine accessibility. 💪🏼

legal banner

Psilocybin production increases 11,900% in 2021

To keep up with the growing demand for psychedelic research, the DEA is yet again increasing the legal production quotas for certain Schedule I substances.

The original proposal for psilocybin was just 50 grams, which increased to 1,500 grams in September. The final quota is now 6,000 grams – a total increase of 11,900%!

Production of both MDMA and DMT increased 6,300% from 50 grams to 3,200 grams.

Industry Quick Hits

Nov 5 – Fluence Raises $1.6M for Psychedelic Therapy Training Read more…

Nov 5 – MAPS and Momentum Events Announce Collaboration on Psychedelic Science 2023 Read more…

Nov 8 – Blackhawk Growth’s (BLR) MindBio Therapeutics Completes Safety Milestone in its Phase 1 Clinical Trials Read more…

Nov 8 – Delic Corp (DELC) Acquisition Of Ketamine Wellness Centers Is Complete Read more…

Nov 8 – NeonMind (NEON) And SRx Health Solutions Announce Strategic Alliance To Establish Specialty Mental Health Clinics For Interventional Psychiatry Treatments Read more…

Nov 9 – MYND Life Sciences (MYND) Executes LOI to Enter into a Clinical Research Collaboration with Revitalist Read more…

Nov 9 – Nova Mentis (NOVA) Files Genetic Neuroinflammatory Disease Patent Read more…

Nov 9 – Herbal Supplement Giant, Irwin Naturals (IWINF), To Enter THC & Psychedelics Industries Read more…

Nov 11 – PharmaTher (PHRM) Announces Positive Research Results for Psilocybin Microneedle Patch Read more…

Video of the Week

DMT Quest Documentary

Playlist of the Week

60s - 70s stoner rock
Posted on

Meet Delic 2022 Happening November 5th & 6th

Meet Delic 2022 Happening November 5th & 6th

Inaugural Meet Delic Experience Sells Out, Becomes World’s Largest Psychedelic and Wellness Event

Organizers Announce New 2022 Dates and Ticket Options and Release Highlights from This Year’s Revolutionary Weekend

Vancouver, BC, November 11, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, has announced the inaugural Meet Delic event that took place on November 6 and 7 sold out, making the psychedelic edutainment experience and business expo the largest in the world. More than 2,500 people visited AREA15 in Las Vegas, Nevada, to attend and experience two days of programs and activities, including 20 hours of talks, panels and discussions at the intersection of psychedelics, wellness, and business by over 60 thought leaders, medical professionals and wellness advocates.

“We’re incredibly humbled and unbelievably inspired by the number of people who came out to Meet Delic and joined the conversation on the power of psychedelics to heal and to remove the stigmas surrounding them,” said Jackee Stang, co-founder of Delic. “The world and our minds have evolved, and so should our medicines. We’re already looking forward to 2022 and how we can continue to show the world the latest in proven health and wellness benefits of psychedelics.”

Meet Delic 2022 will take place on November 5 and 6, 2022, in Las Vegas and advanced tickets can be purchased at Tixr.com.

Here are highlights from this year’s revolutionary weekend of thought-provoking discussions, panels and entertainment:

Lamar Odom, the former NBA star, spoke about his journey to beat addiction, heal PTSD and anxiety through the use of psychedelic medicines and shared a sneak peek of his film, Reborn, which also chronicles his journey, with the film’s director, Zappy Zapolin, in a fireside chat.
Duncan Trussell, comedian and podcaster, brought the house down with a live taping of the ‘Family Hour’ with author and podcaster Aubrey Marcus, Vince Kadlubek, founder of Meow Wolf, and actor Johnny Pemberton.
Guests heard from scholars such as Dr. Carl L. Hart, Ziff Professor at Columbia University and former chair of the Department of Psychology; Dr. Molly Maloof, a lecturer within the Wellness Department of the Medical School at Stanford University; and Dr. Dave Rabin, MD, PhD, co-founder of the Board of Medicine, a nonprofit organization of physicians and scientists establishing the first peer-reviewed, evidence-based clinical guidelines for the production and safe use of currently unregulated alternative medicines, including plant medicines.
Other keynotes included Ifetayo Harvey, Alyson Charles, Chris Ryan, PhD, and George Goldsmith & Ekaterina Malievskaia, M.D., of COMPASS Pathways.
In addition to panels and keynotes, businesses like the Balanced Veterans Network (BVN), a non-profit that creates a safe space for the education, advocacy, and empowerment of alternative therapies for veterans, were onsite showcasing their cutting edge light therapy technology to help treat mental health issues such as PTSD, anxiety, depression, and chronic pain.
Guests experienced high-energy and provocative dance performances by Little Miss Nasty, throbbing beats Mindchatter and DJ David Starfire, and stunning visual experiences by Sporeganic and VJ Jonathan Singer.
Ketamine Wellness Centers (KWC), a subsidiary of Delic Corp, set a record for incoming calls in 24 hours with nearly 2,000 logged during the weekend showing how Delic’s ecosystem concept of businesses really works.
Media Contacts:

Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com, 310.701.9714 & Shae Savin, shaesavinpr@gmail.com

###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Delic Holdings Corp

Posted on

Better Plant Congratulates Affiliate Neonmind On Recent Achievements

Better Plant Congratulates Affiliate Neonmind On Recent Achievements

Vancouver, B.C. – November 10, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FRA: YG3) (“Better Plant” or the “Company”), a wellness company, congratulated its affiliate NeonMind Biosciences Inc. (“NeonMind”) on its recent achievements and advancements toward its drug development program and planned specialty clinics launch.

On November 8, 2021, NeonMind formed an alliance with SRx Health Solutions (“SRx”). SRx is a leading Canadian specialty healthcare services and medical treatment provider, to establish and operate a network of NeonMind-branded specialty clinics to deliver evidence-backed innovative treatments for a variety of mental health needs. NeonMind will leverage SRx’s nationwide network of over 70 clinics, as well as its operational capabilities, to bring NeonMind’s unique treatment protocols to underserved populations in Canada.

Prior to its alliance with SRx, NeonMind was ranked third in Psychedelia Magazine’s “8 Industry Innovators” segment within the magazine’s inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in bringing psychedelic treatments to patients in need through its anticipated specialty mental health clinic launch and its drug development program for novel obesity treatments.

Better Plant congratulates NeonMind for these advancements toward providing integrated mental health services and delivering evidence-backed, innovative treatments tailored to local market needs. NeonMind is a Better Plant portfolio company with an ownership of 26 percent. NeonMind is listed on the CSE under the ticker symbol “NEON”, and on the OTCQB under the ticker symbol “NMDBF”.

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

For more information on NeonMind, go to  www.NeonMindBiosciences.com.

 

About Better Plant Sciences Inc.

Better Plant harnesses plant intelligence and leverages modern science to offer sustainable, plant-based products that are better for health and better for the earth. It makes and sells over 75 proprietary products, all made with 100% natural ingredients, under the brands Jusu, Urban Juve and Wright & Well.  Better Plant operates Jusu Bar, a quick serve restaurant alternative in Victoria, BC, which serves up fresh, healthy, and nutritious options with a focus on Jusu cold-pressed juices. Jusubar.com offers home delivery of refrigerated plant-based beverages consisting of cold-pressed juices and packaged juice cleanses. Through its Shopify enabled eCommerce sites getjusu.com and urbanjuve.com, Better Plant sells plant-based personal care products and cleaning products. Better Plant products are sold through a network of online and brick and mortar retail locations including Whole Foods Market, Pharmasave, Healthy Planet and Vitasave. Better Plant also offers operational, financial, and other services to companies with businesses that align with Better Plant’s mission to help create a better world.

For more information on Better Plant, visit betterplantsciences.com or follow on Instagram, Twitter or LinkedIn.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

Sales Inquiries:

Amber Allen, Head of Sales

amber@betterplantsciences.com

604-808-8118

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation

VANCOUVER, BC, Nov. 9, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has executed a binding letter of intent (“LOI“) with REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist“) (CSE:CALM) (OTC:RVLWF) (FSE: 4DO) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics’ proprietary anti-inflammatory peptide (“MAP“) biomarker. The MAP diagnostic is intended to give health care providers an objective monitoring tool to detect and diagnose mental illness more accurately than the current diagnostic methodology, which can be very subjective. If successful, this biomarker test has the potential to lead to earlier diagnosis of mental illness and ongoing treatment decisions with the goal of improving patient outcomes by providing more tailored and efficacious treatments.

The goal of the collaboration with Revitalist is to utilize their broad network of clinics with patients suffering from mental illness to commence clinical trials to demonstrate MAP’s ability to diagnose and monitor mental health in order to gain approval by the U.S. Food and Drug Administration (“FDA“). The parties anticipate that initial clinical trial will be focused on patients with mental health issues who had previously been infected with COVID-19 and are seeking medical help for post COVID-19 mental health symptoms (“Brain Fog“). The World Health Organization reports that COVID-19 has affected more than 249 million individuals1. Research indicates that approximately 50% on average of those with COVID-19 have reported having lasting effects2. Revitalist has a network of over 2,300 patients through its multiple clinics in the United States, with many of those patients having been previously infected with COVID-19 and seeking specialized treatments to deal with Brain Fog and other lasting effects.

Dr. Lyle Oberg, MD, CEO of MYND stated “A critical step in diagnostics development is demonstrating that an investigational tool produces consistent results. With the new collaboration we intend to design next phase clinical validation studies and take blood samples from existing patients at Revitalist with an expectation that we will submit the MYND biomarker (MAP) data to the FDA for approval in Q2 of 2022. The Company anticipates generating near-term revenue through research and development projects related to MAP. Ultimately, MYND intends to work with physicians to adopt MAP in their practices and provide access to patients and insurance providers for reimbursement when utilizing our proprietary diagnostic. We anticipate that working with Revitalist will be our first of many mental health studies. Their comprehensive network of patients and expert providers will provide the MYND Diagnostics team with optimal research conditions to study MAP in patients so dearly needing better diagnostic and treatment options.”

Kathryn Walker, CEO of Revitalist stated “We are excited to be working with MYND Diagnostics to potentially diagnose and monitor mental health using MAP. Prior to MAP the only diagnostic for mental health was an interview with the patient regarding their history of symptoms, which of course can be very subjective. A diagnostic tool such as MAP would allow for a more objective diagnosis and monitoring, hopefully resulting in a higher level of care and treatments for our patients. One size doesn’t fit all with mental health and treatments that work for some may not work for others. Utilizing MAP would allow us to quickly adjust treatments to better address patient specific mental health issues.”

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc., the parent company of MYND Diagnostics Inc., is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT REVITALIST LIFESTYLE AND WELLNESS

Revitalist Lifestyle and Wellness Ltd. is a publicly traded company, headquartered in Knoxville, Tennessee, with five clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness.

CONTACT INFORMATION

MYND Life Sciences Inc.
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

https://covid19.who.int
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003773#sec016

SOURCE MYND Life Sciences Inc.

Posted on

NeonMind And SRx Health Solutions Announce Strategic Alliance To Establish Specialty Mental Health Clinics For Interventional Psychiatry Treatments

NeonMind And SRx Health Solutions Announce Strategic Alliance To Establish Specialty Mental Health Clinics For Interventional Psychiatry Treatments

Vancouver, B.C. – November 8, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, today announced a strategic alliance with SRx Health Solutions (“SRx”), a leading Canadian specialty healthcare services and medical treatment provider, to establish and operate a network of NeonMind-branded specialty clinics to deliver evidence-backed innovative treatments for a variety of mental health needs. NeonMind will leverage SRx’s nationwide network of over 70 clinics, as well as its operational capabilities, to bring NeonMind’s unique treatment protocols to underserved populations in Canada. The Company expects to select and announce its first clinic location within the SRx network by the end of this calendar year, with a launch in 2022.

Over the past 11 years, SRx has been a trusted service provider in the delivery of specialty patient healthcare across Canada. Under the terms of the agreement, NeonMind and SRx will collaborate to prioritize specialty mental health clinic locations within SRx’s countrywide network of clinics. The alliance enables NeonMind to focus on programmatic design and delivery. Available treatment options will include psychedelic modalities and other newer treatments for mental health. Following the first clinic opening, the Company expects to launch additional clinic locations throughout the course of 2022, continuing to expand locations and services in 2023 and beyond.

“We are proud to partner with SRx as we build out our specialty clinics division,” said Robert Tessarolo, President & CEO of NeonMind. “Establishing these specialty clinics is part of our multi-pronged strategy to bring the therapeutic benefits of psychedelics to patients in need, whether through our specialty clinics for the treatment of neuropsychiatric disorders or with NeonMind’s novel obesity treatments currently in development. SRx’s extensive clinic infrastructure and best-in-class operations will allow us to quickly build out our specialty clinics in a capital-sparring manner to offer patients these innovative treatments in a traditional clinical setting.”

Commenting on the alliance, Mr. Brock Clancy, SRx Vice President of Patient Services and Operations, said, “Recognizing a crucial need for increased support and innovation in mental health treatments, our team has been actively assessing the rapid growth of the market and determining how best to enter this treatment segment. NeonMind’s strategy in this area is unique and compelling, with their initial focus on utilizing already established treatments such as ketamine, esketamine and neurostimulation, while adding additional treatment modalities as they are approved, including psychedelics. Bringing in a partner like NeonMind aligns with our own experiences on how best to deliver specialty treatments while leveraging our existing capabilities and infrastructure. I am excited by this opportunity to work collaboratively with NeonMind to build out and evolve the treatment infrastructure available for interventional psychiatry and psychedelics.”

About SRx Health Solutions Inc.
SRx Health Solutions is Canada’s leading collaborative network of pharmacists and healthcare practitioners delivering innovative, sustainable, and integrated healthcare solutions with the goal of enhancing the wellness of Canadians and supporting those living with chronic illnesses. SRx proudly employs over 400 associates across Canada. SRx have partnerships at 125+ clinic locations made up of, including over 250 nurses who are committed to providing exceptional care to patients coast to coast.  SRx is on a mission to revolutionize healthcare and ensure that all Canadians have access to equal, modern health services.

About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to  www.NeonMindBiosciences.com.

For more information on SRx Health Solutions, go to www.SRxHealth.ca.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

 

Posted on

Delic Corp Acquisition Of Ketamine Wellness Centers Is Complete

Delic Corp Acquisition Of Ketamine Wellness Centers Is Complete

Delic Completes Acquisition of Ketamine Wellness Centers (KWC), Becomes Largest Psychedelic Wellness Chain in United States

National Presence Across 10 States Provides Millions with Access to New Medicines and Treatments for a Variety of Health Conditions Twelve Operational Today, 15 Additional Clinics to Open within 18 Months. Kevin Nicholson, CEO of KWC, Promoted to Chief Operating Officer for Delic Corp

VANCOUVER, BRITISH COLUMBIA – November 9, 2021 – Delic Holdings Corp. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S. KWC is a limited liability corporation formed under the laws of Arizona, which operates 10 ketamine infusion treatment clinics, across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, Utah, and Washington. Delic paid USD$3,293,933 and issued 241,258.50 multiple voting shares. With the close of this transaction, Delic’s consolidated revenue run rate is $11MM.

Transaction Highlights:

  • This acquisition establishes Delic as the largest ecosystem of mental health clinics in the United States.
  • KWC has been operating profitably and expanding significantly with 2020 revenues in excess of USD$3.5MM, on track for USD$4.5MM in 2021. This brings Delic’s pro forma annualized revenue to in excess of USD$8 million.
  • Delic has been focused on opening locations in secondary cities with considerable demand, in an effort to provide access to the most patients.
  • Delic expects to drive considerable patients to KWC through its media platform and build on the existing national leadership position already in place.
  • Established history of providing FDA-approved ketamine infusion services: The management team at KWC has been in business for 6 years expanding services throughout the United States.
  • Management expertise: The acquisition of KWC will add a team of 60+ medical professionals and ‎employees bringing a wealth of industry ‎experience and knowledge to Delic.

Over the last six years, the team at KWC has expanded across the country, from Arizona to Florida, while overseeing 60,000 treatments delivered to date and generating 2020 revenue of USD$3.5MM, trending toward USD$4.5MM in 2021. Prior to this Transaction, KWC has grown without taking outside capital. KWC will operate under the Delic umbrella, under the direction and guidance of Kevin Nicholson, CEO of KWC and the new Chief Operating Officer for Delic Corp. In this new role, Nicholson will focus on the growth and expansion of the psychedelic wellness clinics for the company.

KWC adds to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers LLC (“KIC”) in California and Arizona, cementing its position as the leading and largest wellness provider in the country. Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from new medicines and treatments for a variety of mental health conditions and adds to their position as a central hub of education, media, and cultural conversations around these new medicines and treatments. With a recent successful private placement of $7MM, Delic is actively scouting new locations in cities with a growing patient base.

Matt Stang, co-founder and CEO of Delic commented, “We are thrilled to officially welcome the KWC team to the Delic family and cement our place as the largest network of treatment clinics in the U.S. With the addition of KWC, we can now reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments. As more treatments, such as MDMA and psilocybin, become FDA-authorized for medical use, we have the potential to help millions more people through the clinics.”

“On behalf of the entire KWC team, we are very excited about officially becoming a part of the Delic family,” said Nicholson. “They are an industry leader and uphold the highest standards in developing new, science-backed medicines and treatments and making them more accessible to a wider group of people. With the full support of Delic behind us, KWC will be on an accelerated path to growing our network of clinics throughout the U.S. and bringing more effective, affordable treatments to communities. They will also help us increase awareness of the clinics significantly and drive up patient counts.”

Delic is committed to addressing the mental health crisis by increasing access to science-backed benefits for all and reframing the psychedelic conversation. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) the largest and most accessible network of physical clinics to administer effective treatments, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines, and 3) trusted media and e-commerce platforms and in-person events to market the services directly to patients and consumers and gain data.

Transaction Summary

Under the terms of the Merger Agreement, Delic acquired all of the membership interests of KWC through a reverse triangular merger between KWC and a wholly-owned subsidiary of Delic. (the “Transaction“) for an aggregate purchase price of USD$10,000,000. Delic issued multiple voting shares in the capital of Delic (“Consideration Shares“) to the members of KWC (the “Members“), having an aggregate value of USD$5,000,000, less a holdback equal to USD$1,000,000, at a price per Consideration Share of US $0.1658 (being the ten trading day volume weighed average trading price (“VWAP“) of the Consideration Shares on the Canadian Securities Exchange (the “Exchange“) as of November 3, 2021). Delic further satisfied the purchase price by paying to the Members, an amount equal to USD$5,000,000 in cash consideration with approximately US$3,293,933 paid on the closing date, US$296,541 to be paid on forgiveness of a loan to KWC from The Health Resources and Services Administration,   USD$750,000 to be paid on the date that is 12 months following the closing date, and the final USD$750,000 to be paid on the date that is 24 months following the closing date.

In addition, the Members are eligible to receive additional Consideration Shares upon each new clinic opened by KWC that posts three consecutive months of profitability and minimum revenue of USD$135,000, during those three months, such additional Consideration Shares to have an aggregate value of USD$100,000 per clinic opening, based on a price per share equal to the 10 trading day VWAP of the Consideration Shares on the Exchange immediately prior to the date such milestone is achieved. The milestones are subject to an aggregate cap of 30 new clinic milestones or USD$3,000,000 in additional Consideration Shares.

The Members have agreed that any Consideration Shares issued will be ‎subject to a contractual hold ‎‎period, with 10% of the share consideration to be released on the date that is six months and one day following closing, ‎and 15% ‎released every six months thereafter over a period ‎of 36 months. In addition, Members have agreed to enter into voting support agreements with Delic having a term of two years, pursuant to which the Members will ‎vote as directed by the board of directors of ‎Delic, subject to customary carve-outs.

About Ketamine Wellness Centers

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 10 clinic locations serving communities across eight states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. KWC has provided over 60,000 treatments to clinically eligible patients, from young adults to seniors, in addition to developing specialized programs for veterans and first responders. The KWC team, including a core group of physicians, psychologists, clinicians, and executives, is dedicated to providing value-based, personalized, clinically controlled ketamine infusion care for people suffering from treatment-resistant depression, anxiety, PTSD, OCD and chronic pain. KWC’s scalable business and treatment model is designed for further rapid expansion along with breakthrough innovations in effective therapies and services.

About Delic Corp, Inc.

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses. 

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, including opening 15 additional clinics over 18 months, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to:  incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: the potential impact of the announcement or consummation of milestone payments on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Media & Investor Relations Contact

Rich Rodriguez

rich@deliccorp.com 

Posted on

Novamind Reports FY2021 Financial Results and Operating Highlights

Novamind Reports FY2021 Financial Results and Operating Highlights

  • Industry-leading revenue, $6,069,247 in FY2021
  • Total working capital of $9,680,431 to fund operations
  • Expanded network to six clinics and three clinical research sites
  • Contracted for eight clinical trials
  • Granted DEA Schedule 1 licenses for psilocybin research

 

TORONTO, ON / November 5, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, reported its audited financial results for the twelve months ended June 30, 2021 (“FY2021”). All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.

Yaron Conforti, CEO and Director, commented: “Novamind had strong financial and operating performance in its first year as a public company. Our unique business model serving both patients and drug developers is growing significantly, reflected by an expanded clinic network, new clinical programs and research partnerships, and strong additions to our staff and leadership. I want to thank our patients, employees, partners and investors, and look forward to rapidly expanding our model to meet demand for psychedelic medicine and other innovative mental health treatments.”

Today the Company filed its financial statements later than anticipated due to unforeseen delays with its audit. The Company has since resolved the situation, and going forward, will take the required corrective measures.

FY2021 Operating Results and Subsequent Events

Clinic Division

  • Strengthened Novamind’s clinic network with the addition of two clinics; all six locations offer a variety of innovative mental health services, individualized treatment plans and speciality programming for treatment-resistant illnesses
  • Updated guidance for opening new clinics, adjusting for construction and supply chain disruptions caused by the COVID-19 pandemic:
    • Clinic #7, Salt Lake City, Utah, to open in December 2021
    • Clinic #8, Park City, Utah, to open in early 2022
  • Opened a dedicated client call center to centralize clinic administration services and maintain excellent client services while rapidly growing the Company’s network of clinics

Clinical Research Division

  • Expanded clinical research network to three total sites featuring specialized staff and infrastructure to support the unique needs of psychedelic clinical trials
  • Granted DEA Schedule 1 licenses for psilocybin research, a key prerequisite for hosting clinical trials studying psilocybin-assisted psychotherapy
  • Contracted for eight clinical trials including:
    • Merck’s phase II clinical trial of MK-1942 for treatment-resistant depression
    • Karuna’s phase III clinical trial of KarXT for schizophrenia
    • Bionomics’ phase II clinical trial of BNC210 for post-traumatic stress disorder

Psychedelic Therapy and Programs

  • Launched Frontline Ketamine-Assisted Psychotherapy (Frontline KAP) pilot program to address the widespread COVID-19-related stress and trauma faced by healthcare workers
  • Launched Psychedelic Palliative Care by Novamind, a specialty program to research and scale access to mental healthcare for patients with chronic and serious illness

Strategic Investments

  • Invested US$1,000,000 in Alto Neuroscience, which is developing a pipeline of precision psychiatry medicines using its proprietary AI-based brain biomarker platform
  • Invested AU$965,400 in Bionomics, a biopharmaceutical company focused on central nervous system disorders, alongside investors including Apeiron Investments, Biotech Value Fund, Merck, Mike Novogratz, and Peter Thiel
  • Realized +60% return divesting holdings in the Synthesis Institute, a psychedelic retreat company based in the Netherlands, to focus on Novamind’s U.S. network of clinics and clinical research sites

Capital Markets Activities

  • Listed for trading on the Canadian Securities Exchange (CSE) on January 5, 2021
  • Uplisted to the OTCQB Venture Market, a U.S. trading platform and received Depository Trust Company (DTC) eligibility
  • Closed an oversubscribed private placement, raising gross proceeds of $10,000,000
  • Included in the AdvisorShares Psychedelics ETF trading on the NYSE

FY2021 Financial Highlights

  • Total revenue of $6,069,247, including revenue from four clinics
    • Clinic #5, Draper, Utah, opened on July 29, 2021
    • Clinic #6, Murray, Utah, opened on September 30, 2021
  • Debt-free balance sheet with $5,426,286 in cash and $2,975,329 in marketable securities
    • On August 11, 2021, the Company completed the sale of its investment in the Synthesis Institute realizing gross proceeds of approximately $1,760,000
  • Total working capital of $9,680,431 to fund operations

The following table presents selected financial information from Novamind’s audited financial statements for the twelve months ended June 30, 2021. The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available under Novamind’s SEDAR profile at www.sedar.com.

AFS 2021

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

NeonMind Biosciences Named As A Top Industry Innovator In Inaugural Issue Of Psychedelia Magazine

NeonMind Biosciences Named As A Top Industry Innovator In Inaugural Issue Of Psychedelia Magazine

Announces Participation in Microdose’s Wonderland: Miami on November 8-9, 2021

Vancouver, B.C. – November 5, 2021: NeonMind Biosciences Inc. (CSE: NEON)(OTC: NMDBF) (FFE: 6UF) (“NeonMind” ), an integrated drug development and wellness company, today announced that NeonMind was ranked third in Psychedelia Magazine’s “8 Industry Innovators” segment within the magazine’s inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in bringing psychedelic treatments to patients in need through its anticipated specialty mental health clinic launch and its drug development program for novel obesity treatments.

Separately, Rob Tessarolo, President & CEO of NeonMind, will participate in Microdose’s Wonderland: Miami, the nation’ largest psychedelic medicine business event, which brings together an impressive group of global psychedelic medicine leaders, including scientists and researchers, as well as, investors, entrepreneurs, therapists, patients, and government officials, all championing the growth of the psychedelic medicine industry. Mr. Tessarolo will be participating in one-on-one meetings during the event.

“We are honored to be ranked as a top industry innovator in Psychedelia Magazine, which is a testament to our strategy of pursuing unique modalities across the psychedelic treatment spectrum,” said Robert Tessarolo, President & CEO of NeonMind. “As we are advancing quickly across our drug development program and planned specialty clinics launch, we look forward to sharing our updates with industry participants at the Wonderland event in Miami.”

Wonderland: Miami will be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 8-9, 2021.

For more information regarding the event or to schedule a one-on-one meeting with management, please contact KCSA Strategic Communications at NeonMind@KCSA.com.

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to  www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com 

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications 

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.